Novo Nordisk has opened a new late-stage study testing lower doses of its Wegovy pill, according to a U.S. clinical trials database. The company wants to find the smallest dose that still helps patients lose weight, which could shape how the oral version reaches the market. This news arrives alongside a busy stretch across the GLP-1 industry, from a Hims & Hers CEO interview to a drug discontinuation and stock moves at two competitors. Together, these updates give a fuller picture of where treatment options and access stand right now.
The study reflects a common question in drug development: whether a lower dose can still deliver meaningful results while possibly reducing side effects. Wegovy's injectable form already comes in a range of doses, and finding the right starting point for the pill version matters for both effectiveness and tolerability. Patients who experience nausea or other digestive side effects at higher doses might benefit if a smaller amount proves just as effective for weight loss. The trial's results won't be available right away, but they could influence how doctors prescribe the oral Wegovy once it becomes more widely available. For now, the study is a signal that Novo Nordisk is still refining how this drug will work for the widest range of patients.
Andrew Dudum used the CNBC interview to address three separate pressures facing his company at once: the FTC's lawsuit, questions about compounded GLP-1 drugs, and how artificial intelligence fits into the business. Compounded versions of GLP-1 medications have drawn scrutiny across the industry, and Hims & Hers has been part of that conversation given its role in prescribing and distributing these treatments. The FTC lawsuit adds a legal dimension to that scrutiny, and how the company responds publicly may affect its reputation as much as any legal outcome. Dudum's willingness to discuss all three topics together suggests the company sees them as connected challenges rather than isolated issues. Readers who use telehealth platforms for GLP-1 access may want to follow how this case develops, since it could shape rules for the whole industry.
Patients currently taking Saxenda have several months of notice before the January discontinuation, which gives time to talk with a doctor about switching to another option. Novo Nordisk will continue to offer other GLP-1 medications, so patients won't be left without alternatives from the same company. Anyone affected should raise the change early with their prescriber, since switching medications can involve adjusting doses and monitoring how the body responds to a new drug. Insurance coverage may also differ between medications, so it is a good idea for patients to check with their plan before making a switch. Planning ahead now can help avoid a gap in treatment when Saxenda leaves the market.
Investors have taken notice as Eli Lilly's stock gains ground on Novo Nordisk's Wegovy, with the company drawing attention as a potential entry point for traders watching the weight-loss drug competition. This kind of stock movement often reflects broader confidence in a company's pipeline and market position rather than any single announcement. For patients, the competition between Lilly and Novo Nordisk may matter less directly, but it can influence pricing, availability and how aggressively each company markets its products. As both companies compete for share in the weight-loss drug category, that rivalry could shape what options and pricing look like for patients down the road. Market watchers will likely keep a close eye on how this competition plays out in the coming months.
The Phase 3 win comes from Amylyx testing its GLP-1 drug specifically in patients who have undergone bariatric surgery, a group that can face hypoglycemia as a complication after the procedure. Reducing hypoglycemia in this population addresses a specific medical need separate from weight loss itself, showing that GLP-1 drugs may have applications beyond their most common use. The strong trial results sent Amylyx's stock sharply higher, reflecting investor optimism about the drug's potential path toward approval. This result also points to how GLP-1 medications continue to find new uses in different patient populations facing different health challenges. Patients who have had bariatric surgery and struggle with hypoglycemia may want to ask their doctor whether this kind of treatment could eventually become relevant to their care.
Taken together, these developments show an industry still working out basic questions, from optimal dosing to legal challenges to how competition between companies affects patients. Anyone currently on a GLP-1 medication, whether by injection or expecting a pill form in the future, should stay in close contact with their doctor as new research and changes to product lineups continue to unfold. The most useful step for readers is to ask specific questions about how any of these changes might apply to their own treatment plan, since these industry-wide shifts don't always translate directly into changes for an individual patient's care.
Key details
Novo Nordisk is testing lower doses of the Wegovy pill to see how low can still work.
Hims & Hers CEO Andrew Dudum addressed the FTC lawsuit, compounded GLP-1s, and AI on CNBC.
Saxenda will be discontinued in January, though other GLP-1 options remain.
Eli Lilly's stock is drawing fresh attention as it gains ground on Novo Nordisk's Wegovy.
Amylyx's GLP-1 drug reduced hypoglycemia in bariatric surgery patients, lifting its stock.
Read this on GLP-1 Nation: https://glp1nation.com/edition/24